{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T10:07:21Z","timestamp":1793614041453,"version":"4.5.0"},"reference-count":75,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1097\/hjh.0b013e32834f6e00","type":"journal-article","created":{"date-parts":[[2012,1,21]],"date-time":"2012-01-21T07:17:17Z","timestamp":1327130237000},"page":"647-654","source":"Crossref","is-referenced-by-count":16,"title":["Inhibition of the renin\u2013angiotensin\u2013aldosterone system"],"prefix":"10.1097","volume":"30","author":[{"given":"Massimo","family":"Volpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H. Jan","family":"Danser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00ebl","family":"Menard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Waeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik N.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210208","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0033-0620(78)90025-7","article-title":"Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14225, captopril) in hypertensive patients.","volume":"21","author":"Case","year":"1978","journal-title":"Prog Cardiovasc Dis"},{"key":"R2-2-20210208","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(79)91897-X","article-title":"Improvement of chronic congestive heart-failure by oral captopril.","volume":"1","author":"Turini","year":"1979","journal-title":"Lancet"},{"key":"R3-2-20210208","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"R4-2-20210208","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"R5-2-20210208","first-page":"331","article-title":"Angiotensin-II receptor blockers: benefits beyond blood pressure reduction J Hum H","volume":"19","author":"Volpe","year":"2005","journal-title":"ypertens"},{"key":"R6-2-20210208","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1056\/NEJM197408222910805","article-title":"The renin-angiotensin system (first of two parts).","volume":"291","author":"Oparil","year":"1974","journal-title":"N Engl J Med"},{"key":"R7-2-20210208","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1152\/physrev.00036.2005","article-title":"Physiology of local renin-angiotensin systems.","volume":"86","author":"Paul","year":"2006","journal-title":"Physiol Rev"},{"key":"R8-2-20210208","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00109-008-0336-0","article-title":"Update on tissue renin-angiotensin systems.","volume":"86","author":"Bader","year":"2008","journal-title":"J Mol Med"},{"key":"R9-2-20210208","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","article-title":"Renin-angiotensin system revisited.","volume":"264","author":"Fyhrquist","year":"2008","journal-title":"J Intern Med"},{"key":"R10-2-20210208","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MED.0b013e3283390fa4","article-title":"Aldosterone and cardiovascular disease.","volume":"17","author":"Carey","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R11-2-20210208","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.0954-6820.1982.tb01961.x","article-title":"Blood pressure in relation to the renin-angiotensin-aldosterone system.","volume":"211","author":"Ljungman","year":"1982","journal-title":"Acta Med Scand"},{"key":"R12-2-20210208","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1161\/CIRCULATIONAHA.106.655688","article-title":"The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes. Part I. Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).","volume":"114","author":"Dzau","year":"2006","journal-title":"Circulation"},{"key":"R13-2-20210208","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/eurheartj\/ehr003","article-title":"Renal function and target organ damage in hypertension.","volume":"32","author":"Ruilope","year":"2011","journal-title":"Eur Heart J"},{"key":"R14-2-20210208","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","article-title":"Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document.","volume":"27","author":"Mancia","year":"2009","journal-title":"J Hypertens"},{"key":"R15-2-20210208","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","article-title":"Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.","volume":"165","author":"Turnbull","year":"2005","journal-title":"Arch Intern Med"},{"key":"R16-2-20210208","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.mcna.2009.02.001","article-title":"The kidney, hypertension, and remaining challenges.","volume":"93","author":"Khosla","year":"2009","journal-title":"Med Clin North Am"},{"key":"R17-2-20210208","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/HJH.0b013e32832e9500","article-title":"Bottom blood pressure or bottom cardiovascular risk How far can cardiovascular risk be reduced J H","volume":"27","author":"Zanchetti","year":"2009","journal-title":"ypertens"},{"key":"R18-2-20210208","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/01.CIR.102.13.1556","article-title":"Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: a role of tissue angiotensin II.","volume":"102","author":"Van kats JP, Duncker","year":"2000","journal-title":"Circulation"},{"key":"R19-2-20210208","first-page":"805","article-title":"The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences Eur Heart","volume":"30","author":"Klotz","year":"2009","journal-title":"J"},{"key":"R20-2-20210208","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"R21-2-20210208","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R22-2-20210208","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM199005313222203","article-title":"Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.","volume":"322","author":"Levy","year":"1990","journal-title":"N Engl J Med"},{"key":"R23-2-20210208","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/080370501753400629","article-title":"Renal participation in cardiovascular risk in essential hypertension.","volume":"10","author":"Ruilope","year":"2001","journal-title":"Blood Press"},{"key":"R24-2-20210208","first-page":"564","article-title":"Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996).","volume":"13","author":"Schmieder","year":"1998","journal-title":"Transplant"},{"key":"R25-2-20210208","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","article-title":"A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am J Med"},{"key":"R26-2-20210208","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1001\/jama.292.19.2343","article-title":"Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.","volume":"292","author":"Okin","year":"2004","journal-title":"JAMA"},{"key":"R27-2-20210208","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","article-title":"Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.","volume":"45","author":"Wachtell","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R28-2-20210208","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review.","volume":"329","author":"Strippoli","year":"2004","journal-title":"BMJ"},{"key":"R29-2-20210208","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/HJH.0b013e32833c206d","article-title":"Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockade.","volume":"28","author":"Menne","year":"2010","journal-title":"J Hypertens"},{"key":"R30-2-20210208","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1681\/ASN.2005121288","article-title":"Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms.","volume":"17","author":"Stehouwer","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R31-2-20210208","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1681\/ASN.2010091001","article-title":"On behalf of the ONTARGET InvestigatorsChanges in albuminuria predict mortality and morbidity in patients with vascular disease.","volume":"22","author":"Schmieder","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R32-2-20210208","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/01.HYP.0000154082.72286.2a","article-title":"Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.","volume":"45","author":"Ibsen","year":"2005","journal-title":"Hypertension"},{"key":"R33-2-20210208","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"R34-2-20210208","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.2337\/db06-0827","article-title":"Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.","volume":"55","author":"Persson","year":"2006","journal-title":"Diabetes"},{"key":"R35-2-20210208","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1523-1755.2005.00511.x","article-title":"Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.","volume":"68","author":"Rossing","year":"2005","journal-title":"Kidney Int"},{"key":"R36-2-20210208","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00125-008-1184-8","article-title":"Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.","volume":"52","author":"Schjoedt","year":"2009","journal-title":"Diabetologia"},{"key":"R37-2-20210208","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1097\/HJH.0b013e328277596e","article-title":"Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.","volume":"25","author":"Hollenberg","year":"2007","journal-title":"J Hypertens"},{"key":"R38-2-20210208","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1097\/01.hjh.0000220413.22482.36","article-title":"Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease.","volume":"24","author":"Weinberg","year":"2006","journal-title":"J Hypertens"},{"key":"R39-2-20210208","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/diacare.19.11.1225","article-title":"Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.","volume":"19","author":"Gerstein","year":"1996","journal-title":"Diabetes Care"},{"key":"R40-2-20210208","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/ndt\/15.5.637","article-title":"Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function.","volume":"15","author":"van Paassen","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"R41-2-20210208","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"R42-2-20210208","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/ajh.2011.105","article-title":"Redefining blood pressure targets in high risk patients Lessons from coronary endpoints in recent randomized clinical trials.","volume":"24","author":"Volpe","year":"2011","journal-title":"Am J Hypertens"},{"key":"R43-2-20210208","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1093\/eurheartj\/ehq281","article-title":"Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve.","volume":"31","author":"Zanchetti","year":"2010","journal-title":"Eur Heart J"},{"key":"R44-2-20210208","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1097\/00004872-200111000-00022","article-title":"Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.","volume":"19","author":"Waeber","year":"2001","journal-title":"J Hypertens"},{"key":"R45-2-20210208","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"key":"R46-2-20210208","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"key":"R47-2-20210208","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events.","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"R48-2-20210208","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"R49-2-20210208","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1161\/01.CIR.96.9.3072","article-title":"Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats.","volume":"96","author":"Menard","year":"1997","journal-title":"Circulation"},{"key":"R50-2-20210208","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/hc4101.096153","article-title":"Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.","volume":"104","author":"Schoolwerth","year":"2001","journal-title":"Circulation"},{"key":"R51-2-20210208","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.2337\/diacare.26.8.2268","article-title":"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy.","volume":"26","author":"Rossing","year":"2003","journal-title":"Diabetes Care"},{"key":"R52-2-20210208","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1464-5491.2007.02097.x","article-title":"Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.","volume":"24","author":"Jennings","year":"2007","journal-title":"Diabetes Med"},{"key":"R53-2-20210208","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.ki.5002455","article-title":"Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.","volume":"72","author":"Bakris","year":"2007","journal-title":"Kidney Int"},{"key":"R54-2-20210208","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.03350708","article-title":"for the VA Nephron-D InvestigatorsCombination angiotensin receptor blockers and angiotensin converting enzyme inhibitor for the treatment of diabetic nephropathy VA Nephron-D study.","volume":"4","author":"Freid","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R55-2-20210208","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","article-title":"Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.","volume":"5","author":"Parving","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R56-2-20210208","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.amjcard.2009.07.018","article-title":"Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial ONTARGET).","volume":"104","author":"Cowan","year":"2009","journal-title":"Am J Cardiol"},{"key":"R57-2-20210208","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004872-200018010-00013","article-title":"Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.","volume":"18","author":"Ruilope","year":"2000","journal-title":"J Hypertens"},{"key":"R58-2-20210208","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"R59-2-20210208","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjhyper.2006.06.003","article-title":"Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.","volume":"20","author":"Pool","year":"2007","journal-title":"Am J Hypertens"},{"key":"R60-2-20210208","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"R61-2-20210208","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3317\/jraas.2007.028","article-title":"Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.","volume":"8","author":"Uresin","year":"2007","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R62-2-20210208","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy.","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"R63-2-20210208","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1161\/CIRCULATIONAHA.108.767202","article-title":"Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.","volume":"117","author":"Fisher","year":"2008","journal-title":"Circulation"},{"key":"R64-2-20210208","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1021\/ml200137x","article-title":"Discovery of VTP-27999, an alkyl amine renin inhibitor with potential for clinical utility.","volume":"2","author":"Jia","year":"2011","journal-title":"ACS Med Chem Lett"},{"key":"R65-2-20210208","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJM198505303122202","article-title":"Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications.","volume":"312","author":"Luetscher","year":"1985","journal-title":"N Engl J Med"},{"key":"R66-2-20210208","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s001250051260","article-title":"Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus.","volume":"42","author":"Deinum","year":"1999","journal-title":"Diabetologia"},{"key":"R67-2-20210208","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/01.hjh.0000209989.59230.2e","article-title":"Conformational changes in prorenin during renin inhibition in vitro and in vivo.","volume":"24","author":"Menard","year":"2006","journal-title":"J Hypertens"},{"key":"R68-2-20210208","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1161\/ATVBAHA.108.164210","article-title":"Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells.","volume":"28","author":"Batenburg","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R69-2-20210208","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI0214276","article-title":"Pivotal role of the reninprorenin receptor in angiotensin II production and cellular responses to renin.","volume":"109","author":"Nguyen","year":"2002","journal-title":"J Clin Invest"},{"key":"R70-2-20210208","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/HJH.0b013e32832810ed","article-title":"Aldosterone-receptor antagonism in hypertension.","volume":"27","author":"Jansen","year":"2009","journal-title":"J Hypertens"},{"key":"R71-2-20210208","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00877755","article-title":"Escape of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implication for therapy.","volume":"9","author":"Pitt","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"key":"R72-2-20210208","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/00005344-198211000-00014","article-title":"Antihypertensive therapy with MK 421: angiotensin-renin relationship to evaluate efficacy of converting enzyme blockade.","volume":"4","author":"Biollaz","year":"1982","journal-title":"J Cardiovasc Pharmacol"},{"key":"R73-2-20210208","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/00004872-200105000-00001","article-title":"Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift.","volume":"19","author":"Epstein","year":"2001","journal-title":"J Hypertens"},{"key":"R74-2-20210208","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R75-2-20210208","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004872-201204000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:33:49Z","timestamp":1786048429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004872-201204000-00002"}},"subtitle":["is there room for dual blockade in the cardiorenal continuum?"],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e32834f6e00","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}